Places Archive - Airflow 3 Clinical Trial

Showing results 1 - 10 of 16

Royal Brompton & Harefield NHS Foundation Trust (Chelsea and Westminster Hospital NHS Foundation Trust)

March 29, 2017/in /by Airadmin

CHU de Paris – Hôpital Bichat Claude Bernard

March 29, 2017/in /by Airadmin

CHU de Strasbourg – Nouvel Hôpital Civil

March 29, 2017/in /by Airadmin

CHU de Reims – Hôpital Maison Blanche

March 29, 2017/in /by Airadmin

CHRU de Lille-Hôpital Calmette

March 29, 2017/in /by Airadmin

CHU de Grenoble – Hôpital Michallon

March 29, 2017/in /by Airadmin

Klinikverbund Kempten Oberallgäu

March 29, 2017/in /by Airadmin

Ruhrlandklinik Essen

March 29, 2017/in /by Airadmin

Thoraxklinik Heidelberg

March 29, 2017/in /by Airadmin

Asklepios-Fachkliniken Munchen Gauting

March 29, 2017/in /by Airadmin

Common potential risks associated with the TLD procedure include, but are not limited to, worsening of COPD symptoms (shortness of breath, increased cough, COPD exacerbations), coughing up blood tinged mucous, difficulty swallowing, chest pain, upset stomach or feeling of fullness, trouble processing food, and fever.

Nuvaira® Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).

© 2022 Nuvaira®, Inc. All rights reserved. Privacy Terms of Use